Amorphous Pharmaceutical Materials Assessing emerging applications
Amorphous Pharmaceutical Materials Assessing emerging applications, methodologies, techniques and challenges. 24th - 25th January 2011, BSG Conference Centre, London, UK Key Speakers: Ljiljana Harding, Inhalation & Devices Centre of Emphasis, Pfizer, Franco Sartor, Principal scientist , GlaxoSmithKline, Sigrid Stokbroekx, Research Fellow, Johnson & Johnson Pharmaceutical R&D, Dr. Rolf Hilfiker, Vice President Head of Department Solid-State Development, Solvias, Roger Parker, Senior Scientist, Food Structure and Health Programme, Institute of Food Research, Dr. Simon Gaisford, Senior Lecturer in Pharmaceutics, The School of Pharmacy, University of London Mark Saunders, Owner, co-founder and Development Director, Kuecept, Robert Whittock, IP/IT Practice Group, Freshfields Bruckhaus Deringer LLP, Wouter Pors, Attorney, Bird & Bird, Michael Gamlen, Managing Director, Pharmaceutical Development Services, Prof. Graham Buckton, Chief Executive Officer, Pharmaterials, Dr. Andreas Kordikowski, R&D Director, Activery Biotech, Dr. Filipe Gaspar, Head of Particle Design, Hovione Bertrand Gellie, Director of Organic Chemistry, European Patent Office. Conference Introduction, Amorphous Pharmaceutical Materials, 24th - 25th January 2011, London, UK. With the continuous increase in the number of insoluble developmental drug molecules and growing regulatory scrutiny over pharmaceutical solids, the use of amorphous solids is steadily rising in the pharmaceutical companies. This conference combines presentations on the approaches to amorphous detection and quantitation within GSK, and clinical advice and practical tips from Pfizer and Johnson & Johnson. The biopharmaceutical implications for development of amorphous solid solution intermediates will be discussed and strategies to protect and commercialise innovations in amorphous materials will be presented.During the two days you will be exposed to several analytical strategies to protect and commercialise innovations in amorphous materials. Amorphous Pharmaceutical conference will provide an enlightening and thought-provoking forum with a series of case studies ranging from amorphous formulation to novel amorphous microparticle technology. (http://www.bharatbook.com/detail.asp?id=132812&rt=Conference-on-Amorphous-PharmaceuticalMaterials.html) Reasons to register today: • Understand the use of isothermal calorimetry to characterise stability of amorphous pharmaceuticals. • Implement the latest technological developments. • Discuss the best approaches to control and stabilise amorphous drug forms. • Examine the quantifi cation of amorphous content. file:///C|/Documents%20and%20Settings/user29/Desktop...ce%20on%20Amorphous%20Pharmaceutical%20Materials.htm (1 of 6)7/27/2010 2:41:21 PM